Association of bile acid receptor TGR5 variation and transit in health and lower functional gastrointestinal disorders

Neurogastroenterology and Motility

Volumn 23, Issue 11, 2011, Pages 995-

  Camilleri, M ^a   Vazquez Roque, M I ^a   Carlson, P ^a   Burton, D ^a   Wong, B S ^a   Zinsmeister, A R ^b  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

^b Mayo Clinic College of Medicine   (United States)

Author keywords

Colon; Diarrhea; GpBAR1; Intestine

Indexed keywords

MEMBRANE RECEPTOR; PROTEIN TGR5; UNCLASSIFIED DRUG;

ADULT; ARTICLE; COLONIC TRANSIT; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTESTINE TRANSIT TIME; IRRITABLE COLON; LOWER FUNCTIONAL GASTROINTESTINAL DISEASE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; BILE ACIDS AND SALTS; CONSTIPATION; DIARRHEA; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRANSIT; GENE FREQUENCY; GENETIC VARIATION; HUMANS; IRRITABLE BOWEL SYNDROME; MIDDLE AGED; RECEPTORS, G-PROTEIN-COUPLED;

EID: 80053909415     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2011.01772.x     Document Type: Article

References (28)

1. Claudel T, Staels B, Kuipers F. The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol 2005; 25: 2020-30.
2. Wang H, Chen J, Hollister K, Sowers LC, Forman BM. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 1999; 3: 543-53.
3. Maruyama T, Miyamoto Y, Nakamura T et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun 2002; 298: 714-9.
4. Kawamata Y, Fujii R, Hosoya M et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem 2003; 278: 9435-40.
5. Kuipers F, Stroeve JH, Caron S, Staels B. Bile acids, farnesoid X receptor, atherosclerosis and metabolic control. Curr Opin Lipidol 2007; 18: 289-97.
6. Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun 2005; 329: 386-90.
7. Bajor A, Gillberg PG, Abrahamsson H. Bile acids: short and long term effects in the intestine. Scand J Gastroenterol 2010; 45: 645-64.
8. Poole DP, Godfrey C, Cattaruzza F et al. Expression and function of the bile acid receptor GpBAR1 (TGR5) in the murine enteric nervous system. Neurogastroenterol Motil 2010; 22: 814-25.
9. Talley NJ, Phillips SF, Wiltgen CM et al. Assessment of functional gastrointestinal disease: the bowel disease questionnaire. Mayo Clin Proc 1990; 65: 1456-79.
10. Odunsi-Shiyanbade ST, Camilleri M, McKinzie S et al. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol 2009; 8: 159-65.
11. Andresen V, Camilleri M, Kim HJ et al. Is there an association between GNbeta3-C825T genotype and lower functional gastrointestinal disorders? Gastroenterology 2006; 130: 1985-94.
12. Camilleri CE, Carlson PJ, Camilleri M et al. A study of candidate genotypes associated with dyspepsia in a U.S. community. Am J Gastroenterol 2006; 101: 581-92.
13. Camilleri M, Carlson P, Zinsmeister AR et al. Mitochondrial DNA and gastrointestinal motor and sensory functions in health and functional gastrointestinal disorders. Am J Physiol 2009; 296: G510-6.
14. Kim HJ, Camilleri M, Carlson PJ et al. Association of distinct alpha(2) adrenoceptor and serotonin transporter polymorphisms with constipation and somatic symptoms in functional gastrointestinal disorders. Gut 2004; 53: 829-37.
15. Manabe N, Wong BS, Camilleri M, Burton D, McKinzie S, Zinsmeister AR. Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort. Neurogastroenterol Motil 2010; 22: 293-e82.
16. Rao AS, Wong BS, Camilleri M et al. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology 2010; 139: 1549-58 and Supplementary Material
17. Burton DD, Camilleri M, Mullan BP, Forstrom LA, Hung JC. Colonic transit scintigraphy labeled activated charcoal compared with ion exchange pellets. J Nucl Med 1997; 38: 1807-10.
18. Cremonini F, Mullan BP, Camilleri M, Burton DD, Rank MR. Performance characteristics of scintigraphic transit measurements for studies of experimental therapies. Aliment Pharmacol Ther 2002; 16: 1781-90.
19. Deiteren A, Camilleri M, Bharucha AE et al. Performance characteristics of scintigraphic colon transit measurement in health and irritable bowel syndrome and relationship to bowel functions. Neurogastroenterol Motil 2010; 22: 415-23.
20. Camilleri M. Scintigraphic biomarkers for colonic dysmotility. Clin Pharmacol Ther 2010; 87: 748-53.
21. Weir BS Hardy-Weinberg disequilibrium. In: Weir BS, ed. Genetic Data Analysis II: Methods for Discrete Population Genetic Data. Sunderland, MA: Sinauer Associates Publishers, 1996: 98-101.
22. Hov JR, Keitel V, Laerdahl JK et al. Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis. PLoS ONE 2010; 5: e12403.
23. Keely SJ. Missing link identified: GpBAR1 is a neuronal bile acid receptor. Neurogastroenterol Motil 2010; 22: 711-7.
24. Odunsi-Shiyanbade ST, Camilleri M, McKinzie S et al. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol 2010; 8: 159-65.
25. Bampton PA, Dinning PG, Kennedy ML, Lubowski DZ, Cook IJ. The proximal colonic motor response to rectal mechanical and chemical stimulation. Am J Physiol 2002; 282: G443-9.
26. Fonseca VA, Handelsman Y, Staels B. Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. Diabetes Obes Metab 2010; 12: 384-92.
27. Prawitt J, Caron S, Staels B. Bile acid metabolism and the pathogenesis of type 2 diabetes. Curr Diab Rep 2011; 11: 160-6.
28. Knop FK. Bile-induced secretion of glucagon-like peptide-1: pathophysiological implications in type 2 diabetes? Am J Physiol 2010; 299: E10-3.